(Q58841511)

2

0 references

Özgür Çakıcı

3

0 references

Burak Tanyıldız

4

0 references

Okan Olcaysu

5

0 references

Halil Hüseyin Çağatay

Expert Review of Ophthalmology

6

0 references

publication date

22 March 2014

0 references

published in

0 references

volume

9

0 references

issue

2

0 references

page(s)

139-143

0 references

cites work

The pathogenesis of edema in diabetic maculopathy

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

Immunological mechanisms in the pathogenesis of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

Association of vitreous inflammatory factors with diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

Diabetic maculopathy. A critical review highlighting diffuse macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

VEGF164Is Proinflammatory in the Diabetic Retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

Progressive Enlargement of Laser Scars Following Grid Laser Photocoagulation for Diffuse Diabetic Macular Edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

Macular function after intravitreal triamcinolone acetonide injection for diabetic macular oedema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

Intravitreal bevacizumab treatment for refractory diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

Short-term efficacy of intravitreal bevacizumab for the treatment of macular edema due to diabetic retinopathy and retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439

Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17469899.2014.900439